The independent source for health policy research, polling, and news.
821 - 840 of 1,303 Results
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
KHN correspondent Emmarie Huetteman appeared on the C-SPAN program “Washington Journal,” where she fielded viewers’ calls about high drug prices and industry criticism.
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
The state’s governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nation’s drug-pricing problem.
Most hearings before the U.S. House and Senate are routine affairs. But a few tense moments featuring everyone from Hillary Clinton to tobacco CEOs drew the attention of millions of Americans.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
In an emerging new tactic against the rising toll of opioid deaths, California, Ohio, Virginia and Arizona are among the states requiring physicians to offer patients naloxone when they give them prescriptions for the powerful painkillers. The Food and Drug Administration is weighing a national recommendation to do so.
Medicare and many private insurers view prescribing drugs to improve sexual function as a lifestyle issue that’s not medically necessary to pay for.
The “Medicare–for-all” debate is already in full swing, but what does that phrase even mean? Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner for a beginner’s guide to the next big health policy debate. For “extra credit,” the panelists provide their favorite health policy stories of the week, and as a special Valentine’s Day bonus, their favorite #HealthPolicyValentines.
Unwilling to wait for federal action, California Gov. Gavin Newsom says he has a plan that could extract discounts from drugmakers and save the state money — one he hopes other states can join.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
© 2026 KFF